Patent US4853224A successfully refreshed from Google Patents.
US4853224A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Biodegradable ocular implants
Assignee: VISIONEX A CA CORP
•
Filing: 1987-12-22
•
Granted: 1989-08-01
•
Expires: 2007-12-22
Abstract
Abstract Microencapsulated drugs are proposed for introduction into the chambers of the eye for therapeutic purposes. The administration of drugs is controlled and maintained for long periods of time, while ensuring the substantial absence of significant levels outside the site of administration.
Inventors
- 👤 Vernon G. Wong
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 15:42
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0048; A61K9/0051; A61K9/10; A61K9/127; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1641; A61K9/1647
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
53 words
A method for treating an eye condition which comprises: implanting at least one of the anterior or posterior chamber of an eye at least one microencapsulated drug as particles of not greater than about 300 micrometers, said particles comprising said drug and a pharmacologically acceptable biodegradable polymer which is degraded in the eye.
Claim 2
Independent Claim
53 words
A method for treating an eye condition which comprises: implanting at least one of the anterior or posterior chamber of an eye at least one microencapsulated drug as particles of not greater than about 300 micrometers, said particles comprising said drug and a pharmacologically acceptable biodegradable polymer which is degraded in the eye.
Claim 3
Dependent Claim
13 words
A method according to claim 1, wherein said polymer is a condensation polymer.
Claim 4
Dependent Claim
12 words
A method according to claim 2, wherein said polymer is a polyester.
Claim 5
Dependent Claim
15 words
A method according to claim 3, wherein said polyester comprises an hydroxyaliphatic carboxylic acid monomer.
Claim 6
Dependent Claim
14 words
A method according to claim 4, wherein said hydroxyaliphatic carboxylic acid is lactic acid.
Claim 7
Dependent Claim
15 words
A method according to claim 1, wherein said particle comprises a pharmacologically acceptable buffering agent.
Claim 8
Dependent Claim
13 words
A method according to claim 1, wherein said drug is a cytotoxic agent.
Claim 9
Dependent Claim
16 words
A method according to claim 1, wherein said steroid is hydrocortisone or a pharmacologically acceptable ester.
Claim 10
Dependent Claim
12 words
A method according to claim 7, wherein said cytotoxic agent is methotrexate.
Claim 11
Dependent Claim
25 words
A method according to claim 1, wherein an effective dosage for treatment of said condition is maintained in said chamber for at least one month.
Claim 12
Dependent Claim
22 words
A method according to claim 10, wherein said particle is of an average size in the range of 10 to 250 micrometers.
Claim 13
Dependent Claim
13 words
A method according to claim 1, wherein said drug is a growth factor.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-07-31 | 1993-01-30 | 1993-08-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-07-31 | 1997-01-30 | 1997-08-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-07-31 | 2001-01-30 | 2001-08-01 | $7700.00 | Window Closed / Lapsed |